This week, the overall grades of five Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
This week, Momenta Pharmaceuticals (NASDAQ:MNTA) falls to a D (“sell”), worse than last week’s grade of C (“hold”). Momenta Pharmaceuticals is a biotechnology company. In Portfolio Grader’s specific subcategories of Earnings Growth, Earnings Momentum, Margin Growth, and Sales Growth, MNTA also gets F’s. The stock price has dropped 8.7% over the past month, worse than the 4% decrease the Nasdaq has seen over the same period of time. To get an in-depth look at MNTA, get Portfolio Grader’s complete analysis of MNTA stock.
Vical Inc.‘s (NASDAQ:VICL) rating weakens this week, dropping to a D versus last week’s C. Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The stock price has fallen 20.4% over the past month. The stock has a trailing PE Ratio of 84.80. For a full analysis of VICL stock, visit Portfolio Grader.
Progenics Pharmaceuticals (NASDAQ:PGNX) earns a D this week, moving down from last week’s grade of C. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The stock receives F’s in Earnings Momentum, Earnings Revisions, Equity, and Sales Growth. For more information, get Portfolio Grader’s complete analysis of PGNX stock.
OncoGenex Pharmaceuticals (NASDAQ:OGXI) experiences a ratings drop this week, going from last week’s C to a D. OncoGenex Pharmaceuticals is a biopharmaceutical company that develops and commercializes new cancer therapies that address treatment resistance in cancer patients. The stock gets F’s in Earnings Momentum, Equity, and Cash Flow. Investors seem to agree with the downgrade and have pushed down the share price 13.1% over the past month. For a full analysis of OGXI stock, visit Portfolio Grader.
YM BioSciences (AMEX:YMI) earns a D this week, falling from last week’s grade of C. YM BioSciences is a drug development company, engages in advancing three clinical-stage hematology and cancer-related products. The stock also gets an F in Equity. To get an in-depth look at YMI, get Portfolio Grader’s complete analysis of YMI stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
